In the present study, we found that 26.8% childhood LCH patients presented with BRAF V600E mutations, 7% presented with MAP2K1 mutation, where BRAF V600E and MAP2K1 mutations were predictors of inferior PFS, OS and worse treatment efficacy after a 6-week treatment. Here, MAP2K1 is linked to Langerhans cell histiocytosis.